[EN] SULFENAMIDE COMPOUNDS FOR PHOTOTHERAPY<br/>[FR] COMPOSÉS DE SULFÉNAMIDE DESTINÉS À UNE PHOTOTHÉRAPIE
申请人:MALLINCKRODT INC
公开号:WO2011060113A1
公开(公告)日:2011-05-19
The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are sulfenamide compounds having an acyclic S-N bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment of a range of pathological conditions, including the treatment of cancers, stensosis and inflammation. The invention further provides preparations and formulations comprising the sulfenamide optical agents and related methods of making and using sulfenamide optical agents in an in vivo or ex vivo biomedical procedure.
Type 1 Phototherapeutic Agents, Part I: Preparation and Cancer Cell Viability Studies of Novel Photolabile Sulfenamides
作者:Amolkumar S. Karwa、Amruta R. Poreddy、Bethel Asmelash、Tien-Sung Lin、Richard B. Dorshow、Raghavan Rajagopalan
DOI:10.1021/ml2001483
日期:2011.11.10
Novel type 1 phototherapeutic agents based on compounds containing S–N bonds (sulfenamides) were synthesized, assessed for free radical generation, and evaluated in vitro for cell death efficacy in four cancer cell lines (U937, HTC11, KB, and HT29). All of the compounds were found to produce copious free radicals upon photoexcitation with UV-A and/or UV-B light, as determined by electron spin resonance